Hims & Hers Health, Inc. (HIMS) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $28.11 (-2.45%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 9, 2026 | Ryan MacDonald | Needham | $30.00 | +6.7% |
| Feb 24, 2026 | Craig Hettenbach | Morgan Stanley | $21.00 | -25.3% |
| Feb 24, 2026 | Jailendra Singh | Truist Financial | $18.00 | -36.0% |
| Feb 10, 2026 | George Hill | Deutsche Bank | $31.00 | +10.3% |
| Feb 9, 2026 | Michael Cherny | Leerink Partners | $20.00 | -28.9% |
| Dec 4, 2025 | Michael Cherny | Leerink Partners | $41.00 | +45.8% |
| Nov 12, 2025 | Craig Hettenbach | Morgan Stanley | $40.00 | +42.3% |
| Nov 4, 2025 | Jailendra Singh | Truist Financial | $37.00 | +31.6% |
| Nov 4, 2025 | Michael Cherny | Leerink Partners | $46.00 | +63.6% |
| Jun 24, 2025 | Jailendra Singh | Truist Financial | $45.00 | +60.1% |
| Jun 4, 2025 | Ryan Macdonald | Needham | $65.00 | +131.2% |
| Feb 19, 2025 | Maria Ripps | Canaccord Genuity | $68.00 | +141.9% |
| Dec 2, 2024 | Maria Ripps | Canaccord Genuity | $38.00 | +35.2% |
| Nov 5, 2024 | Korinne Wolfmeyer | Piper Sandler | $21.00 | -25.3% |
| Nov 5, 2024 | Ryan MacDonald | Needham | $28.00 | -0.4% |
| Oct 29, 2024 | Michael Cherny | Leerink Partners | $26.00 | -7.5% |
| Oct 21, 2024 | Michael Cherny | Bank of America Securities | $25.00 | -11.1% |
| Oct 14, 2024 | Michael Cherny | Bank of America Securities | $23.00 | -18.2% |
| Oct 14, 2024 | Jailendra Singh | Truist Financial | $23.00 | -18.2% |
| Sep 13, 2024 | Allen Lutz | Bank of America Securities | $20.00 | -28.9% |
Top Analysts Covering HIMS
HIMS vs Sector & Market
| Metric | HIMS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.76 | 2.25 | 2.42 |
| Analyst Count | 25 | 8 | 18 |
| Target Upside | +17.3% | +16187.2% | +19.5% |
| P/E Ratio | 57.45 | 3.73 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.63B | $2.76B | $3.01B | 10 |
| 2027-03-31 | $698M | $758M | $819M | 4 |
| 2027-06-30 | $721M | $784M | $847M | 6 |
| 2027-09-30 | $766M | $833M | $900M | 4 |
| 2027-12-31 | $794M | $862M | $932M | 7 |
| 2028-03-31 | $841M | $914M | $988M | 3 |
| 2028-06-30 | $879M | $955M | $1.03B | 5 |
| 2028-09-30 | $905M | $983M | $1.06B | 3 |
| 2028-12-31 | $930M | $1.01B | $1.09B | 6 |
| 2029-12-31 | $4.09B | $4.73B | $5.37B | 5 |
| 2030-12-31 | $4.01B | $4.63B | $5.26B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.18 | $0.51 | $0.72 | 9 |
| 2027-03-31 | $0.08 | $0.09 | $0.10 | 2 |
| 2027-06-30 | $0.13 | $0.14 | $0.16 | 2 |
| 2027-09-30 | $0.22 | $0.24 | $0.27 | 2 |
| 2027-12-31 | $0.27 | $0.30 | $0.34 | 2 |
| 2028-03-31 | $0.17 | $0.19 | $0.21 | 3 |
| 2028-06-30 | $0.20 | $0.23 | $0.25 | 3 |
| 2028-09-30 | $0.35 | $0.39 | $0.43 | 3 |
| 2028-12-31 | $0.36 | $0.40 | $0.44 | 3 |
| 2029-12-31 | $1.14 | $1.38 | $1.63 | 1 |
| 2030-12-31 | $1.54 | $1.86 | $2.19 | 1 |
Frequently Asked Questions
What is the analyst consensus for HIMS?
The consensus among 25 analysts covering Hims & Hers Health, Inc. (HIMS) is Hold with an average price target of $29.67.
What is the highest price target for HIMS?
The highest price target for HIMS is $68.00, set by Maria Ripps at Canaccord Genuity on 2025-02-19.
What is the lowest price target for HIMS?
The lowest price target for HIMS is $13.00, set by Korinne Wolfmeyer at Piper Sandler on 2024-05-07.
How many analysts cover HIMS?
25 analysts have issued ratings for Hims & Hers Health, Inc. in the past 12 months.
Is HIMS a buy or sell right now?
Based on 25 analyst ratings, HIMS has a consensus rating of Hold (2.76/5) with a +17.3% upside to the consensus target of $29.67.
What are the earnings estimates for HIMS?
Analysts estimate HIMS will report EPS of $0.51 for the period ending 2026-12-31, with revenue estimated at $2.76B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.